We tested the hypothesis that TRPC3, a member of the canonical transient receptor potential (TRP) family of channels, mediates agonist-induced depolarization of arterial smooth muscle cells (SMCs). In support of this hypothesis, we observed that suppression of arterial SMC TRPC3 expression with antisense oligodeoxynucleotides significantly decreased the depolarization and constriction of intact cerebral arteries in response to UTP. In contrast, depolarization and contraction of SMCs induced by increased intravascular pressure, i.e., myogenic responses, were not altered by TRPC3 suppression. Interestingly, UTP-evoked responses were not affected by suppression of a related TRP channel, TRPC6, which was previously found to be involved in myogenic depolarization and vasoconstriction. In patch-clamp experiments, UTP activated a whole cell current that was greatly reduced or absent in TRPC3 antisense-treated SMCs. These results indicate that TRPC3 mediates UTP-induced depolarization of arterial SMCs and that TRPC3 and TRPC6 may be differentially regulated by receptor activation and mechanical stimulation, respectively. transient receptor potential; nonselective cation channels; vascular smooth muscle; uridine triphosphate; vasoconstriction; antisense oligodeoxynucleotides ARTERIAL DIAMETER is a primary effector of blood flow and pressure. Influx of extracellular Ca 2ϩ through voltage-dependent L-type Ca 2ϩ channels located in the arterial smooth muscle cell (SMC) plasma membrane is central in the control of cerebrovascular arterial diameter (24). Membrane depolarization opens L-type Ca 2ϩ channels, and their steep voltage dependence means that small changes in membrane potential (V m ) dramatically affect channel open probability, Ca 2ϩ influx, and vascular tone. Various agonists that bind to receptors on the SMC plasma membrane and activate the phospholipase C-inositol 1,4,5-trisphosphate-diacylglycerol signal transduction pathway [norepinephrine (8, 23, 25), histamine (3, 7), 5-hydroxytryptamine (23), and UTP (39)] are known to depolarize and constrict arterial SMCs. An unresolved issue in vascular biology is the identification and characterization of the membrane channels responsible for agonist-induced depolarization of arterial smooth muscle.
transient receptor potential; nonselective cation channels; vascular smooth muscle; uridine triphosphate; vasoconstriction; antisense oligodeoxynucleotides ARTERIAL DIAMETER is a primary effector of blood flow and pressure. Influx of extracellular Ca 2ϩ through voltage-dependent L-type Ca 2ϩ channels located in the arterial smooth muscle cell (SMC) plasma membrane is central in the control of cerebrovascular arterial diameter (24) . Membrane depolarization opens L-type Ca 2ϩ channels, and their steep voltage dependence means that small changes in membrane potential (V m ) dramatically affect channel open probability, Ca 2ϩ influx, and vascular tone. Various agonists that bind to receptors on the SMC plasma membrane and activate the phospholipase C-inositol 1,4,5-trisphosphate-diacylglycerol signal transduction pathway [norepinephrine (8, 23, 25) , histamine (3, 7), 5-hydroxytryptamine (23) , and UTP (39) ] are known to depolarize and constrict arterial SMCs. An unresolved issue in vascular biology is the identification and characterization of the membrane channels responsible for agonist-induced depolarization of arterial smooth muscle.
The recent identification of mammalian homologs of the Drosophila transient receptor potential (TRP) channel in native vascular SMCs raised the interesting possibility that mammalian TRPCs mediate agonist-induced membrane depolarization. Members of the canonical TRP channel family (TRPC), specifically TRPC3 and TRPC6, are found in rat aorta (5) , preglomerular resistance vessels (5), rabbit and mouse portal veins (12) , and rat cerebral artery (40) . TRPC3 and TRPC6 channels are activated by diacylglycerol independent of PKC (37) and give rise to a cation current that has relatively low selectivity for Ca 2ϩ over Na ϩ (10) . Recently, TRPC6 channels were reported to mediate a nonselective cation current activated by ␣ 1 -adrenergic receptor stimulation in rabbit portal vein SMCs (12) and in rat embryonic aorta SMCs exposed to vasopressin (14) . A clear role for TRPC6 regulation of myogenic tone in rat cerebrovascular resistance arteries has also been demonstrated (40) . However, in contrast to TRPC6, a role for TRPC3 channels in native vascular SMCs has not been established.
The focus of the present study was to determine whether TRPC3 or TRPC6 channels are involved in agonist-induced depolarization of cerebral artery SMCs. We observed that antisense oligodeoxynucleotide (ODN) suppression of TRPC3, but not TRPC6, expression attenuated UTP-induced depolarization and constriction of cerebral arteries and abolished a UTP-activated ion current in isolated arterial SMCs. These results demonstrate that TRPC3 is specifically involved in agonist-evoked arterial SMC constriction.
MATERIALS AND METHODS

Animals and tissues.
Twelve-to 16-wk-old male Sprague-Dawley rats (Charles River Laboratories, St. Constant, PQ, Canada) were studied. All animal use procedures were in accordance with institutional guidelines and approved by the institutional Animal Care and Use Committee at the University of Vermont.
Rats were euthanized with an injection of pentobarbitone sodium (150 mg/kg ip) followed by exsanguination. The brain was removed, and cerebellar and cerebral arteries (125-225 m diameter) were dissected free in ice-cold MOPS-buffered saline solution containing 3 mM MOPS, 145 mM NaCl, 5 mM KCl, 1 mM MgSO 4 ⅐ 7H2O, 2.5 mM CaCl2, 1 mM KH2PO4, 0.02 mM EGTA, 2 mM pyruvate, 5 mM glucose, and 1% bovine serum albumin (pH 7.4).
RT-PCR analysis. RNA was prepared from arteries or isolated SMCs with use of the RNeasy kit (Qiagen, Valencia, CA). Then 3-5 l of each first-strand cDNA reaction was placed in 40 -45 l of a PCR solution (Applied Biosystems, Branchburg, NJ) containing 1.4 mM MgCl 2, 20 M forward and reverse primers (Great American Gene, Ramona, CA), 0.25 mM deoxynucleotide triphosphates, 1ϫ reaction buffer, and 2.5 U of AmpliTaq Gold DNA polymerase. PCR were hot started (94°C for 10 min) and then exposed to 35-40 cycles of 94°C for 60 s, 60°C for 90 s, and 72°C for 60 s. Forward and reverse primers specific for TRPC3 were designed using Vector NTI software: 5Ј-CCTGAGCGAAGTCACACTCCCAC-3Ј (forward) and 5Ј-CCACTCTACATCACTGTCATCC-3Ј (reverse). Primers yield product sizes of 529 bp for TRPC3. All reaction products were resolved on 1% agarose gels.
Western analysis. Arterial segments were homogenized in lysis buffer (5 min at 4°C) containing 40 mM 3-(Cyclohexylamino)-1-propanesulfonic acid, 1 mM dl-dithiothreitol, 10 mM EDTA, 15 mM MgCl 2, 115 mM NaCl, 1 mM Na-orthovanadate, 1 mM NaF, 2.5 mM urea, 0.25% deoxycholate, 10% glycerol, 1% NP-40, 0.2% SDS, and 1:50 mammalian protease inhibitor cocktail (Sigma, St. Louis, MO). Equal amounts of sample protein were separated on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane. The membranes were exposed to a TRPC3 or TRPC6 polyclonal antibody (anti-rabbit, 1:200 dilution; Alomone Labs, Jerusalem, Israel) and a glyceraldehyde dehydrogenase (GAPDH) monoclonal antibody (antimouse, 1:1,000 dilution; Chemicon Labs, Temecula, CA). Alexa Fluor 680 goat anti-rabbit (Molecular Probes, Eugene, OR) and IRDye 800 anti-mouse (Rockland Immunochemicals, Gilbertsville, PA) were used to fluorescently label the TRPC3 and GAPDH antibodies, respectively. The density of signals specific for the TRPC3 and GAPDH bands in a given lane on a membrane was measured after the membrane was scanned with an Odyssey infrared imaging system (Li-COR Biosciences, Lincoln, NE).
Immunohistochemistry. Freshly isolated arterial segments were fixed for 15 min in phosphate-buffered saline containing 4% paraformaldehyde and exposed to the primary antibody (1:250 dilution of rabbit anti-TRPC3; Alomone Labs) overnight. Alexa Fluor 680 goat anti-rabbit (Molecular Probes) was used to fluorescently label the TRPC3 antibody. The arteries were examined at ϫ40 magnification using a laser scanning confocal microscope (model 1000, Bio-Rad).
ODN sequences and reverse permeabilization. TRPC6 sense and antisense ODNs were designed as previously described (40): 5Ј-CCCTAGCCAGTCTGAACTCC-3Ј and 5Ј-GCACACGCAGCCT-CTTCAC-3Ј (sense) and 5Ј-GGAGTTCAGACTGGCTAGGG-3Ј and 5Ј-GCACACGCAGCCTCCTTCAC-3Ј (antisense). TRPC3 sense and antisense ODNs were designed on the basis of the rat TRPC3 gene (27) : 5Ј-TATTCCAGTTCATGGTTCTC-3Ј and 5Ј-TGTCTGGTC-GTGTTGGTCGT-3Ј (sense) and 5Ј-GAGAACCATGAACTGGAATA-3Ј and 5Ј-ACGACCAACACGACCAGACA-3Ј (antisense). The last five bases on the 5Ј and 3Ј ends were phosphorothioated to limit ODN degradation. For some experiments, fluorescein isothiocyanate was conjugated to the 5Ј end to allow for histological assessment of cellular uptake of the ODNs. All ODNs were synthesized and HPLC purified commercially by Qiagen (Alameda, CA).
Sense and antisense ODNs (2 M) were introduced into the arterial SMCs via a reversible-permeabilization procedure (16). The arterial segments were then organ cultured for 3 days in DMEM-F-12 with L-glutamine (2 mM), penicillin (50 U/ml), and streptomycin (50 g/ml) before use.
Patch-clamp electrophysiology. Single SMCs were enzymatically isolated from sense-or antisense-treated cerebral arteries using an isolation solution of the following composition: 60 mM NaCl, 58 mM sodium glutamate, 5.6 mM KCl, 2 mM MgCl2, 10 mM glucose, 0.1 mM CaCl2, and 10 mM HEPES (pH 7.4), with 0.5 mg/ml papain and 1 mg/ml dithioerythritol. After 10 min, arterial segments were placed in a second isolation solution containing 0.1 mM CaCl2 and a collagenase type F-hyaluronidase mixture (1 mg/ml each). Trituration was performed with a polished wide-bore pipette, and the cells were stored on ice and used on the same day.
Whole cell ionic currents were measured using the perforated-patch method in the presence or absence of 30 M UTP. Recording electrodes (4-to 7-M⍀ resistance) were pulled from borosilicate glass. Plated cells were voltage clamped and held at Ϫ60 mV for 15 min before experimentation; whole cell currents were monitored while voltage was slowly ramped (from Ϫ120 to ϩ20 mV at 0.167 mV/ms); currents were not leak subtracted. The bath solution contained (in mM) 120 NaCl, 1.2 MgCl2, 1.8 CaCl2, 10 HEPES (pH 7.4), and 10 glucose. The pipette solution contained 120 mM CsCl, 3 mM MgCl 2, 0.1 mM EGTA, 10 mM HEPES (pH 7.2), 10 mM glucose, and 200 g/ml amphotericin B. A series resistance of ϳ40 M⍀ was accepted for all perforated-patch-clamp experiments. Membrane currents were filtered at 1 kHz, digitized at 5 kHz, and stored in a personal computer system for subsequent analysis. pClamp 8.1 and Clampfit 8.1 (Axon Instruments) were used to record and analyze membrane currents. Cell capacitance was measured with the cancellation circuitry of the voltage-clamp amplifier (Axopatch 200A, Axon Instruments). All current recordings were performed at room temperature (22°C).
Diameter and membrane potential recordings. Endothelial celldenuded artery segments were mounted on glass pipettes in an arteriograph chamber (Living Systems, Burlington, VT), pressurized to 20 mmHg (with no flow), and superfused with warm (37°C), gassed (95% O 2-5% CO2) physiological saline solution containing (in mM) 119 NaCl, 4.7 KCl, 24 NaHCO3, 0.2 KH2PO4, 1.1 EDTA, 1.2 MgSO4, 1.6 CaCl2, and 10.6 glucose (pH 7.4). In experiments using Ca 2ϩ -free physiological saline solution, CaCl2 was omitted and 3 mM EGTA and 30 M diltiazem were added. The endothelium was removed as previously described (33) . For verification of endothelial cell removal, the arteries were pressurized to 60 mmHg and allowed to develop myogenic tone before the vessels were exposed to 1 M UTP. Absence of a dilation or biphasic constrictor response to 1 M UTP indicated successful endothelial cell removal (20, 21) .
Arterial diameter or V m of sense-and antisense-treated arteries was measured in the absence (control) or presence of UTP (0.1-10 M). V m was measured by insertion of a sharp glass electrode (ϳ100-M⍀ resistance) containing 0.5 M KCl into the vessel wall. The criteria for successful vascular SMC impalement were 1) a sharp negative V m deflection on entry, 2) a stable potential for Ն1 min after entry, and 3) a sharp positive V m deflection on removal. Measurements were made using an electrometer (World Precision Instruments), and the data were recorded via computer using Axotape and Dataq software. Arterial diameter was measured using a video dimension analyzer (IonOptix, Milton, MA).
Chemicals, drugs, and enzymes. Buffer reagents, collagenase type F, hyaluronidase, dithioerythritol, and UTP were purchased from Sigma. Papain was obtained from Worthington Biochemical (Lakewood, NJ). Nisoldipine (a gift from Miles Pharmaceuticals, West Haven, CT) was dissolved in ethyl alcohol to a final solvent concentration of 0.1%. All other compounds were dissolved in the appropriate salt solution.
Statistical analysis. Values are means Ϯ SE, and n indicates the number of animals. Changes in arterial diameter were measured as percent constriction, calculated as follows %constriction ϭ initial diameter Ϫ diameter after UTP exposure initial diameter ϫ 100
Student's t-test was used to compare sense-with antisense-treated experimental groups. In experiments where the treatment group was exposed to more than one concentration of UTP, a two-way repeatedmeasures ANOVA was used. Means were considered significantly different at P Յ 0.05.
RESULTS
Expression of TRPC3 in rat cerebral arteries. RT-PCR was used to determine whether mammalian TRPC3 mRNA transcripts were expressed in cerebral arteries of adult male rats. Message for TRPC3 was identified in intact cerebral arteries as well as in SMCs isolated from these arteries (Fig. 1A) . Western analysis of arterial homogenates detected a protein band of ϳ120 kDa that was not detected when the TRPC3 antibody was preabsorbed with the peptide antigen (Fig. 1B) . Immuno-fluorescent labeling of intact cerebral arteries revealed a circumferential staining pattern for TRPC3 consistent with localization of TRPC3 to the arterial smooth muscle (Fig. 1C) .
Suppression of TRPC3 expression in cerebral artery. Specific pharmacological inhibitors are not available to test the functional role of TRPC3 channels in vascular smooth muscle. Therefore, we employed an antisense ODN approach that we successfully used in previous studies to reduce TRPC6 channel expression and function (40) . In the present study, we found that TRPC3 antisense ODNs decreased the expression of TRPC3 compared with sense-treated arteries. Fluorescein-labeled ODNs are taken up by cerebral arterial SMCs, and the uptake is significantly enhanced by reversibly permeabilizing the arteries (Fig. 2A) . Western analysis showed that antisense treatment had no effect on the expression of GAPDH but reduced the density of the TRPC3 protein band after 3 days of organ culture (Fig. 2B) ; the TRPC3-to-GAPDH ratio was 42.5 Ϯ 11.4% less in antisense-treated (n ϭ 4) than in sensetreated (n ϭ 4) samples (Fig. 2C) . On the basis of previous studies (22, 34, 40) , changes in protein expression of this magnitude are likely to be associated with altered activity of signaling systems that involve the protein of interest. TRPC3 antisense ODNs had no effect on the expression of TRPC6 in cerebral arterial SMCs (Fig. 2, B and C) .
Evidence of a functional role for TRPC3 in rat cerebral arteries. We observed that UTP-induced depolarization of SMCs was significantly less in antisense-than in sense-treated arteries (Fig. 3A ) at all UTP concentrations tested. In addition to attenuating UTP-induced depolarization of arterial SMCs, suppression of TRPC3 expression also reduced the constrictor responses to UTP over that same concentration range (Fig. 3B) . Compared with sense-treated arteries, UTP-induced constrictions of TRPC3 antisense-treated arteries were reduced by ϳ61% in response to 10 Ϫ6 M UTP and by 37% in response to Fig. 2 . Reversible permeabilization (R-P) enhances oligodeoxynucleotide (ODN) uptake, and ODNs suppress TRPC3 expression in rat cerebral artery. A: entry of fluorescein-labeled ODNs is greatly enhanced by reversible permeabilization compared with arteries exposed to ODNs in PBS for an equivalent amount of time. B: Western blot showing effect of TRPC3 antisense ODNs on TRPC3 and TRPC6 (red) and GAPDH (green) protein expression in cerebral artery. C: summary data for the effect of TRPC3 sense and antisense ODNs on TRPC3 and TRPC6 protein expression in rat cerebral artery. TRPC-to-GAPDH band density ratio was determined for each sense and antisense sample and then multiplied by 100 to yield a whole number. Values are means Ϯ SE. *Significant difference (P Յ 0.05) between sense (n ϭ 4) and antisense (n ϭ 4) samples. 10 Ϫ5 M UTP. Antisense ODNs had no generalized inhibitory effect on arterial contractility. Elevation of extracellular KCl from 5 to 60 mM decreased the resting diameter of sense-and antisense-treated arteries by 58 Ϯ 12% (n ϭ 6) and 57 Ϯ 9% (n ϭ 7), respectively. Similarly, pressure-induced depolarization and myogenic tone were identical in TRPC3 sense-and antisense-treated arteries. The arterial SMCs depolarized by 14 Ϯ 1 mV in TRPC3 sense-treated (n ϭ 6) and antisensetreated (n ϭ 7) arteries and developed 26 Ϯ 4% (TRPC3 sense) and 27 Ϯ 5% (TRPC3 antisense) myogenic tone when intravascular pressure was increased from 20 to 80 mmHg.
Agonist-induced depolarization is not mediated by TRPC6 in cerebral artery. We previously showed that TRPC6 is involved in pressure-induced depolarization and myogenic tone in cerebral arteries (40) . Interestingly, in the present study, we found that exposure to UTP significantly depolarized the SMCs, but there was no difference between the TRPC6 senseand antisense-treated groups (Fig. 4A) . Furthermore, TRPC6 antisense treatment did not affect the magnitude of constriction after exposure to increasing concentrations of UTP (Fig. 4B) , indicating that TRPC6 is not involved in UTP-evoked depolarization or constriction of these arteries.
TRPC3 antisense ODNs inhibit a UTP-activated whole cell current.
In further support of the involvement of TRPC3 in the depolarization and constriction induced by UTP, we have found that 30 M UTP activates a whole cell current in SMCs isolated from TRPC3 sense-treated arteries (8 of 9 cells, voltage ramps from Ϫ120 to 20 mV; Fig. 5A ). This response to UTP was absent in three of five SMCs and was greatly suppressed in two of five SMCs isolated from TRPC3 antisense-treated arteries (Fig. 5, B and C) . These results demonstrate the presence of a UTP-activated current in cerebrovascular SMCs and strongly suggest that this current is mediated by TRPC3 channels.
Further evidence of a role for TRPC3 in agonist-evoked depolarization. In a final series of experiments, TRPC3 senseand antisense-treated arteries were exposed to UTP concentrations sufficient to constrict the arteries by ϳ40%. In the continued presence of UTP, sense-and antisense-treated arteries were exposed to 10 Ϫ6 M nisoldipine to inhibit voltagedependent L-type Ca 2ϩ channels. Consistent with the proposal that agonist-induced membrane depolarization contributes to vasoconstriction, we observed that blockade of the L-type Ca 2ϩ channels with nisoldipine partially reversed the contractile response to UTP in sense-treated (Fig. 6 ), but not antisensetreated, arteries. These results strongly suggest that TRPC3 channels mediate UTP-induced depolarization of arterial SMCs and that the depolarization accounts for a substantial component of the overall vasoconstrictor response. showing greater membrane depolarization in sense-treated (n ϭ 6) than in antisense-treated (n ϭ 5) cerebral arteries exposed to increasing concentrations of UTP. Resting membrane potentials (Vm) were Ϫ50 Ϯ 1 and Ϫ49 Ϯ 2 mV in sense-and antisense-treated arteries, respectively. B: summary data of the decrease in vessel diameter (percent constriction) of TRPC3 sense-treated (n ϭ 4) and antisense-treated (n ϭ 4) arteries exposed to increasing concentrations of UTP. Initial internal diameters were 173 Ϯ 16 and 187 Ϯ 15 m in senseand antisense-treated arteries, respectively (no significant difference). Values are means Ϯ SE. *Significant difference (P Յ 0.05) between sense-and antisense-treated vessels.
DISCUSSION
The major new finding of the present study is that TRPC3 channels contribute to UTP-induced depolarization and constriction of cerebral arterial SMCs. Several observations support this conclusion: 1) TRPC3 mRNA and protein were expressed in SMCs and cerebral arteries of adult rats (Fig. 1). 2) Suppression of TRPC3 channel expression significantly attenuated UTP-induced depolarization and constriction (Fig.  3). 3) Suppression of TRPC3 channel expression nearly eliminated UTP-induced whole cell currents in isolated SMCs (Fig.  5) . 4) Inhibition of voltage-dependent L-type Ca 2ϩ channels partially reversed UTP-induced vasoconstriction when TRPC3 channels were present, but not when their expression was suppressed.
Expression of TRPC3 in vascular SMCs. We detected TRPC3 mRNA and protein expression in rat cerebral artery SMCs (Fig. 1, A and B) . TRPC3 mRNA and/or protein expression has been detected in other vascular SMCs, including those of the rat aorta (5), rat pulmonary artery (17, 26) , mouse portal vein (12) , canine renal artery (38) , rat preglomerular resistance vessels (5) , and rat caudal artery (2) . The presence of TRPC3 mRNA and/or protein in a number of vascular SMC types suggests that the contribution of TRPC3 to vascular function may be widespread.
Receptor activation of TRPC3 channels. Our present findings demonstrate for the first time that TRPC3 channels are involved in receptor-mediated vasoconstriction. Receptor coupling and activation of TRPC3 have been clearly demonstrated using overexpression approaches in cultured cells (1, 10, 18, 35, 37, 41) . Evidence for such coupling has also been obtained for native cell systems. For instance, a TRPC3 channel-dependent cation current has been observed in rat neonatal pontine neurons after activation of TrkB by brain-derived nerve growth factor (11) . TRPC3 channels also contribute to a cation conductance-associated regulation of nuclear factor of activated T cells of skeletal muscle gene expression (29) and the contraction of myometrial smooth muscle during parturition (4, 36) . These observations raise the interesting possibility that activation of TRPC3 channels after receptor stimulation may be a rather common occurrence across the diversity of cell types known to express TRPC3 channels.
In the present study, antisense suppression of TRPC3 decreased UTP-induced depolarization of cerebral artery SMCs (Figs. 3 and 4) , whereas antisense suppression of TRPC6 was without effect. This suggests that TRPC6 channels are not involved in the pyrimidine receptor-mediated response in these cells. Also, suppression of TRPC3 had no effect on pressureinduced depolarization or the development of myogenic tone by cerebral artery SMCs. Suppression of TRPC6, however, decreases pressure-induced depolarization of cerebral artery . TRPC3 antisense suppresses UTP-induced currents in freshly isolated vascular SMCs. Cells were patched in the perforated-patch configuration, and whole cell currents were recorded during voltage ramps from Ϫ120 to ϩ20 mV from a holding potential of Ϫ60 mV. A and B: ramp currents (I) in the absence (control) and presence of UTP for cells from sense-treated and antisense-treated vessels, respectively. C: means Ϯ SE of UTP-induced current density (difference currents) at Ϫ120 mV. *Significant difference (P Յ 0.05) between TRPC3 sense-treated (n ϭ 9) and antisense-treated (n ϭ 5) SMCs.
SMCs (40) . Together, these findings suggest that different excitatory stimuli, in this case UTP and pressure, are coupled to distinct populations of TRPC channels in cerebral artery SMCs. Similarly, coupling of specific receptor types (e.g., purinergic vs. adrenergic) to individual TRPC channel isoforms may vary in different artery SMC types (e.g., cerebral vs. systemic and conduit vs. resistance) or in arterial compared with venous SMCs. Such differences might account for the absence of a UTP-induced depolarizing current mediated by TRPC6 in cerebral artery SMCs, when a TRPC6-mediated depolarizing current is clearly present in rabbit portal vein SMCs exposed to an ␣ 1 -adrenergic agonist (12) .
Contribution of TRPC3 to agonist-induced depolarization and constriction. Depolarization and activation of L-type Ca 2ϩ channels in vascular SMCs is a well-established mechanism of vasoconstriction (24) . Micromolar concentrations of UTP depolarize arterial SMCs by ϳ20 mV (Figs. 3 and 4) (19, 39) , which is sufficient to open L-type Ca 2ϩ channels to permit extracellular Ca 2ϩ influx and constriction ( Fig. 6 ) (15) . UTP also activates a TRPC3-mediated inwardly rectifying current in isolated SMCs (Fig. 5) . Thus a major conclusion of the present study is that TRPC3 channels are primary mediators of UTPinduced depolarization of cerebral artery smooth muscle. Arterial SMC depolarization is also observed in response to other receptor agonists, such as norepinephrine (8, 23, 25) , histamine (3, 7), and 5-hydroxytryptamine (23), indicating that SMC depolarization is an important component of receptor-mediated vasoconstriction. It will be interesting to determine whether TRPC3 mediates depolarization induced by these and other vasoconstrictor agonists.
Although antisense suppression of TRPC3 channels significantly attenuated an inward current and SMC depolarization in response to UTP, some depolarization was still detectable in the TRPC3 antisense-treated arteries. This was likely due to incomplete TRPC3 channel suppression (Fig. 2) and/or UTPmediated activation of other depolarizing mechanisms (9, 19, 28, 32, 39) . Furthermore, inhibiting L-type Ca 2ϩ channels only partially attenuated UTP-induced vasoconstriction (Fig. 6 ). This illustrates that alternative constrictor mechanisms, such as release of Ca 2ϩ from the sarcoplasmic reticulum (13), altered myofilament Ca 2ϩ sensitivity (31), or inhibition of myosin light chain phosphatase (6, 30) , also regulate vasoconstriction induced by UTP. The relative contributions of these signaling modalities to the overall contractile response of vascular smooth muscle remain to be determined.
Summary. TRPC3 channels can be added to the list of membrane channels that contribute to the ion fluxes controlling arterial diameter. TRPC3 channels are distinctly involved in UTP-induced depolarization and constriction of arterial smooth muscle, whereas TRPC6 channels contribute to the arterial myogenic response. The unique and differential activation of these ion channels by various excitatory stimuli could have important implications concerning the development of new therapeutic strategies targeted to specific vascular SMC constrictor mechanisms in vascular disease states.
